1 / 7

Non-Small Cell Lung Cancer Market Scenario Highlighting Major Drivers and Trends, 2026

One of the major drivers of the non-small cell lung cancer is the strong drug pipeline and recent drug approvals. The innovation of new drugs and their approvals for the treatment of the disease is anticipated to fuel the growth of the market.

Ptsoniya
Download Presentation

Non-Small Cell Lung Cancer Market Scenario Highlighting Major Drivers and Trends, 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Non-Small Cell Lung Cancer Market To Reach USD 10.53 Billion By 2026

  2. Market Summary The Global Non-Small Cell Lung Cancer Market is forecast to reach USD 10.53 Billion by 2026, according to a new report by Reports and Data. Non-small cell lung cancer accounts for approximately 85% of all lung cancers. The rise in the number of people suffering from non-small cell lung cancer is one of the major factors driving the global non-small cell lung cancer drugs market growth. The risk factors such as air pollution, cigarette smoking, passive smoking, and occupational exposure are increasing the incidence of the disease globally.

  3. Our Approach Our Approach Market Summary One of the major drivers of the non-small cell lung cancer is the strong drug pipeline and recent drug approvals. The innovation of new drugs and their approvals for the treatment of the disease is anticipated to fuel the growth of the market. One of the challenges of the non-small cell lung cancer market is the high cost of treatment. The disease can be treated by chemotherapy, surgery, targeted therapies, radiation therapy, and immunotherapy, which is quite expensive. Thus, the high cost of the treatment will hamper the growth of the market. Key participants include Tarceva, Avastin, Gemzar, Alimta, Taxotere, AstraZeneca, Roche, Merck KGa, Nlyte, and Panduit Corp. among others. Request for a sample of this research report @ https://www.reportsanddata.com/sample-enquiry-form/1475

  4. Our Approach Our Approach Market Summary Further key findings from the report suggest Smoking causes ~90% of lung cancer cases. Constant exposure to the high level of air pollution and drinking water with a high level of arsenic increases the odds of lung cancer. The most common type of non-small cell lung cancer are adenocarcinomas, squamous cell carcinoma, and large cell carcinomas. Squamous cell carcinoma is the second most common form of lung cancer. This type of lung cancer is found in the middle of the lungs. It is forecasted to hold a market share of 37% in the year 2026. Adenocarcinoma held a market share of 48% in the year 2018. The disease tends to develop in smaller airways such as bronchioles, breasts, prostate, pancreas, and colon…Continued • • • • To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/non-small-cell-lung-cancer-market

  5. Our Approach Our Approach Market Summary For the purpose of this report, Reports and Data have segmented the global Non-Small Cell Lung Cancer Market on the basis of Histology, Treatment, Drug Class, and Region: Histology Outlook (Revenue, USD Billion; 2016-2026) Squamous Cell Carcinoma Large Cell Carcinoma Adenocarcinoma Treatment Outlook (Revenue, USD Billion; 2016-2026) Surgery Radiation Chemotherapy Targeted Therapy Drugs Order Now @ https://www.reportsanddata.com/checkout-form/1475

  6. Our Approach Our Approach Market Summary Drug Class Outlook (Revenue, USD Billion; 2016-2026) Angiogenesis Inhibitor Epidermal Growth Factor Receptor Blocker Kinase Inhibitor Microtubule Stabilizer Folate Antimetabolites PD-1/ PD-L1 Inhibitor Regional Outlook (Revenue, USD Billion; 2016-2026) North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia)

  7. Our Approach Our Approach About Us About Us Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com

More Related